Gyre Therapeutics, a commercial-stage biopharmaceutical company focused on anti-fibrotic and inflammatory disease therapies, reported its latest quarterly update emphasizing key customers concentrated in the Chinese pharmaceutical market. The company completed the acquisition of Cullgen Inc., bolstering its pipeline and operational capabilities. Revenue remains heavily dependent on three main Chinese pharmaceutical distributors under government procurement programs. Gyre’s strategy combines leveraging its established commercial products with advancing clinical-stage therapeutics like Hydronidone for sustainable growth amid significant competitive and regulatory risks.